All articles tagged: Crohn's disease, unspecified, without complications (K50.90)

In a clinical practice guideline issued by the American Gastroenterological Association (AGA) and published in the January issue of Gastroenterology, recommendations are presented for the management of pouchitis.Edward L. Barnes, M.D., M.P.H., from the University of North Carolina at Chapel Hill, and colleagues developed recommendations

Individuals with inflammatory bowel disease (IBD) universally show increased prescription medication use years before diagnosis, according to a study published in the December issue of the American Journal of Gastroenterology.Linéa Bonfils, M.D., from Aalborg University in Copenhagen, Denmark, and colleagues compared use of any pre

Perfluoroalkyl and polyfluoroalkyl substance (PFAS) exposure is associated with later occurrence of inflammatory bowel disease (IBD), according to a research letter published online Dec. 26 in Clinical Gastroenterology and Hepatology.Manasi Agrawal, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and collea

For patients with inflammatory bowel disease (IBD), phenotype varies by race, and foreign-born patients of all races have later onset and milder disease, according to a study published online Dec. 16 in Gastro Hep Advances.Ali Khalessi, M.D., from the New York University School of Medicine in New York City, and colleagues conducted

For patients with inflammatory bowel disease (IBD), phenotype varies by race, and foreign-born patients of all races have later onset and milder disease, according to a study published online Dec. 16 in Gastro Hep Advances.Ali Khalessi, M.D., from the New York University School of Medicine in New York City, and colleagues conducted

For patients with Crohn disease (CD), biomarkers can inform disease management in symptomatic and asymptomatic disease, according to a clinical practice guideline issued by the American Gastroenterological Association and published in the December issue of Gastroenterology.Ashwin N. Ananthakrishnan, M.B.B.S., from Massachusetts General

Changes in multiple biochemical and hematological parameters occur up to eight years before diagnosis of Crohn disease and up to three years before diagnosis of ulcerative colitis, according to a study published in the Nov. 21 issue of Cell Reports Medicine.Marie Vibeke Vestergaard, from Aalborg University in Copenhagen, Denmark, and co

Histologic inflammation with inflammatory bowel disease (IBD) is an independent risk factor for serious infections, according to a study published online Oct. 29 in Clinical Gastroenterology and Hepatology.Karl Mårild, M.D., Ph.D., from Sahlgrenska Academy in Gothenburg, Sweden, and colleagues assessed whether serious infection risk

Five health conditions are associated with subsequent diagnosis of multiple sclerosis, but they overlap with two other autoimmune diseases, according to a study published online Dec. 5 in Neurology.Octave Guinebretiere, from Sorbonne Université in Paris, and colleagues examined the association between diseases and symptoms diagnosed in

Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve remission, according to a study published in the November issue of the American Journal of Gastroenterology.Andres J. Yarur, M.D., from Cedars Sinai Medical Center

Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later arrhythmias, according to a study published online Oct. 19 in PLOS Medicine.Jiangwei Sun, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues explo

The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. The approval includes indications for adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic a